公开(公告)号：WO2022269393A1

公开(公告)日：2022-12-29

申请号：PCT/IB2022/055149

申请日：2022-06-01

申请人： CRISPR THERAPEUTICS AG

发明人： SLUCH, Valentin ,  SWAIN, Danielle ,  REZANIA, Alireza

IPC分类号： C12N5/0783 ,  A61K35/17 ,  A61P35/00 ,  C07K14/74 ,  C07K14/725 ,  C07K14/5443 ,  C07K14/70539 ,  C07K14/7155 ,  C07K14/8121 ,  C07K2319/00 ,  C07K2319/02 ,  C12N15/625 ,  C12N15/85 ,  C12N15/907 ,  C12N2310/20 ,  C12N2501/115 ,  C12N2501/125 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/165 ,  C12N2501/2303 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/26 ,  C12N2501/415 ,  C12N2501/515 ,  C12N2506/45 ,  C12N2510/00 ,  C12N2800/107 ,  C12N5/0646 ,  C12N5/067 ,  C12N5/0696 ,  C12N9/22

摘要： Provided herein are cells engineered to have improved protection against natural killer cell killing. The cells are engineered to comprise an insertion of a polynucleotide encoding SERPINB9. Also provided herein are methods of making the engineered cells and therapeutic uses of the engineered cells. The engineered cells can also comprise at least one genetic modification within or near at least one gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or component or transcriptional regulator of the MHC-I or MHC-II complex, at least one genetic modification that increases the expression of at least one polynucleotide that encodes a tolerogenic factor, and optionally at least one genetic modification that increases or decreases the expression of at least one gene that encodes a survival factor. The engineered cells can be stem cells and the engineered stem cells can be differentiated into various lineages having protection against NK cell killing.

公开(公告)号：WO2022269019A1

公开(公告)日：2022-12-29

申请号：PCT/EP2022/067303

申请日：2022-06-24

申请人： CYTOVAC A/S

发明人： KIRKIN, Alexei ,  DJANDJOUGAZIAN, Karine

IPC分类号： C12N5/0783 ,  A61P35/00 ,  C12N2501/06 ,  C12N2501/2302 ,  C12N2501/515 ,  C12N5/0638 ,  C12N5/0646

摘要： Provided is a method for preparation of a composition comprising activated human CD8+ lymphocytes with phenotype of stem cell-like memory cells and natural killer (NK) lymphocytes. The method entails use of short-term activation of lymphocytes by CD3/CD28 activating agents followed by treatment with DNA-demethylating agent. The invention also provides a version of the method where addition of a CD3/CD28 activating agent is made a few days after initiation of CD4+ mediated activation of the CD8+ cells; this step is also disclosed as an improvement of related methods where autologous dendritic cells have been used to activate the lymphocytes. Also provided is a method for treatment of cancer using the cells obtained from the process.

公开(公告)号：WO2022246293A8

公开(公告)日：2022-11-24

申请号：PCT/US2022/030394

申请日：2022-05-20

申请人： SANA BIOTECHNOLOGY, INC.

发明人： SCHREPFER, Sonja

IPC分类号： A61K35/17 ,  C12N5/0783 ,  C12N15/00 ,  C07K14/70596 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2506/45 ,  C12N2510/00 ,  C12N5/0636

摘要： Disclosed herein are hypoimmunogenic T cells having reduced expression of RhD antigen for administering to a patient. In some embodiments, the cells are propagated from a primary T cell or a progeny thereof or are derived from an induced pluripotent stem cell (iPSC). In some embodiments, the cells exogenously express CD47 proteins and exhibit reduced expression of MHC class I proteins, MHC class II proteins, or both. In some embodiments, the cells exogenously express one or more chimeric antigen receptors.

公开(公告)号：WO2022232797A2

公开(公告)日：2022-11-03

申请号：PCT/US2022/071950

申请日：2022-04-27

申请人： BAYLOR COLLEGE OF MEDICINE

发明人： QUACH, David H. ,  ROONEY, Cliona M. ,  RAMOS, Carlos A.

IPC分类号： C12N5/0783 ,  A61K35/17 ,  A61K39/245 ,  C07K14/05 ,  A61P35/02 ,  A61K2039/5156 ,  A61K39/001112 ,  A61K39/001129 ,  C07K14/005 ,  C12N2501/2302 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2501/998 ,  C12N2506/11 ,  C12N2510/00 ,  C12N2710/16234 ,  C12N5/0636

摘要： Embodiments of the disclosure encompass methods for generating or expanding a population of immune cells specific for a virus, comprising stimulating immune cells specific for a virus by culturing peripheral blood mononuclear cells (PBMCs) in cell culture medium comprising human platelet lysate in the presence of: (i) one or more peptides corresponding to all or part of one or more antigens of the virus; or (ii) antigen presenting cells (APCs) presenting one or more peptides corresponding to all or part of one or more antigens of the virus. In particular embodiments, the cell culture medium comprises a particular percentage of human platelet lysate and/or the PBMCs are depleted of CD45RA-positive cells, for example.

公开(公告)号：WO2022003152A2

公开(公告)日：2022-01-06

申请号：PCT/EP2021/068315

申请日：2021-07-02

申请人： AARHUS UNIVERSITET ,  REGION MIDTJYLLAND ,  STIPE THERAPEUTICS APS

发明人： HANSEN, Aida Solhøj ,  DELEURAN, Bent Winding ,  JAKOBSEN, Martin Roelsgaard ,  KRAPP, Christian

IPC分类号： C12N5/0783 ,  A61K31/7084 ,  A61K35/17 ,  C12N2501/51 ,  C12N2501/515 ,  C12N5/0636

摘要： This present invention describes extracellular vesicles derived from activated T cells can prime macrophages for enhanced pro-inflammatory response towards stimulation with STING agonists. Further, a direct anti-tumoral effect of extracellular vesicles derived from activated T cells prior to intratumorally injection of cGAMP is demonstrated.

公开(公告)号：WO2021219758A1

公开(公告)日：2021-11-04

申请号：PCT/EP2021/061198

申请日：2021-04-28

申请人： OSPEDALE SAN RAFFAELE S.R.L.

发明人： CAMISA, Barbara ,  CASUCCI, Monica ,  ARCANGELI, Silvia ,  MEZZANOTTE, Claudia ,  FALCONE, Laura ,  BONINI, Maria Chiara

IPC分类号： C12N5/0783 ,  A61K39/00 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K39/001112 ,  A61P35/00 ,  A61P35/02 ,  C07K14/7051 ,  C07K16/2803 ,  C07K2317/622 ,  C07K2319/03 ,  C07K2319/33 ,  C12N2501/2307 ,  C12N2501/515 ,  C12N2510/00 ,  C12N5/0636

摘要： The present invention refers to a method to produce a T cell with advantageous properties. The invention also refers to a T cell or an engineered T cell produced by the method and its use in therapy.

公开(公告)号：WO2021044213A2

公开(公告)日：2021-03-11

申请号：PCT/IB2020/000710

申请日：2020-09-03

申请人： MIGAL-GALILEE RESEARCH INSTITUTE LTD.

发明人： GROSS, Gideon ,  LEVIN, Noam ,  WEINSTEIN-MAROM, Hadas

IPC分类号： C07K14/705 ,  A61K39/00 ,  A61P31/00 ,  A61P31/12 ,  A61P35/00 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783 ,  C12N9/16 ,  A61K2039/5156 ,  A61K39/001102 ,  C07K14/4705 ,  C07K14/70503 ,  C07K14/70507 ,  C07K14/7051 ,  C07K14/70514 ,  C07K14/70517 ,  C07K14/7056 ,  C07K14/70589 ,  C07K14/70596 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/33 ,  C07K2319/41 ,  C07K2319/50 ,  C07K2319/60 ,  C12N2501/515 ,  C12N2510/00 ,  C12N5/0637 ,  C12Y301/03048

摘要： Provided herein are novel blocking chimeric antigen receptors ("bCARs") and immune cells (e.g., effector and regulatory immune cells) that express such bCARs. Such blocking CARs prevent undesired activation of the immune cells, particularly undesired activation of the immune cells against normal tissue in therapeutic applications. Thus, such bCARs advantageously allow for selective immune cell activation only upon interaction with specific target cells (e.g., tumor cell).

公开(公告)号：WO2023019185A1

公开(公告)日：2023-02-16

申请号：PCT/US2022/074784

申请日：2022-08-10

申请人： GENTIBIO, INC.

发明人： NADA, Adel ,  WICKHAM, Tom

IPC分类号： A61K35/17 ,  C12N15/10 ,  C12N15/90 ,  A61K38/46 ,  C07K14/71 ,  C12N15/09 ,  C12P19/34 ,  C12N15/86 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2510/00 ,  C12N5/0637

摘要： Described herein are compositions and methods for producing regulatory T cells (Tregs) with stable immunosuppressive phenotypes by modifying cells to promote expression of TGFβRI, Smad2, and/or Smad3.

公开(公告)号：WO2022204564A2

公开(公告)日：2022-09-29

申请号：PCT/US2022/022030

申请日：2022-03-25

申请人： IOVANCE BIOTHERAPEUTICS, INC.

发明人： SIMPSON-ABELSON, Michelle, R. ,  FRIGAULT, Matthew, J. ,  ROTHBAUM, Wayne, P. ,  WEISER, Michael

IPC分类号： C12N5/0783 ,  A61K35/17 ,  G01N33/50 ,  A61K2039/5158 ,  A61K2039/545 ,  A61K2039/55533 ,  A61K38/2013 ,  A61K39/0011 ,  C12N2501/2302 ,  C12N2501/515 ,  C12N2502/1114 ,  C12N2502/1157 ,  C12N2502/30 ,  C12N2503/00 ,  C12N5/0638 ,  G01N2333/57 ,  G01N2500/10 ,  G01N33/5008 ,  G01N33/5047 ,  G01N33/505 ,  G01N33/6866

摘要： The present invention provides novel processes, compositions, and methods for analyzing or assaying the potency and/or functionality of tumor infiltrating lymphocyte (TIL) products for use in therapy, including human cancer therapy, and analyzing or assaying the potency and/or functionality of other polyclonal products, such as marrow infiltrating lymphocyte (MIL) and peripheral blood lymphocyte (PBL) products. Compositions, methods, and kits for preparing and treating cancer using TIL, MIL, and PBL products are also provided.

公开(公告)号：WO2021229581A2

公开(公告)日：2021-11-18

申请号：PCT/IL2021/050556

申请日：2021-05-13

申请人： YEDA RESEARCH AND DEVELOPMENT CO. LTD. ,  THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH

发明人： FLEISHMAN, Sarel ,  ELAZAR, Assaf ,  WEINSTEIN, Jonathan Y. ,  CALL, Melissa J. ,  CALL, Matthew E. ,  CHANDLER, Nicholas J.

IPC分类号： A61K35/17 ,  C07K14/725 ,  C07K19/00 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K38/00 ,  A61K39/001106 ,  A61P35/00 ,  C07K14/705 ,  C07K14/7051 ,  C07K16/32 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/33 ,  C07K2319/41 ,  C12N2501/515 ,  C12N2510/00 ,  C12N5/0636

摘要： Provided herein is a family of programmable de novo designed transmembranal protein domain polypeptides, and uses thereof in the production of engineered chimeric antigen receptor T (CAR T) cells, which are used, for example, to fight cancer.